These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12087624)

  • 21. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S;
    Cancer Lett; 2008 Jun; 264(1):44-53. PubMed ID: 18280644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly epirubicin in the treatment of gestational breast cancer (GBC).
    Peccatori FA; Azim HA; Scarfone G; Gadducci A; Bonazzi C; Gentilini O; Galimberti V; Intra M; Locatelli M; Acaia B; Rossi P; Cinieri S; Calabrese L; Goldhirsch A
    Breast Cancer Res Treat; 2009 Jun; 115(3):591-4. PubMed ID: 18712595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
    Campora E; Nobile MT; Sertoli MR; Rosso R
    Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
    Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma.
    Beresford M; Lyburn I; Sanghera B; Makris A; Wong WL
    Breast J; 2007; 13(4):424-5. PubMed ID: 17593051
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of pharmorubicin in cancer of the breast].
    Ass NIa; Borisov VI
    Sov Med; 1986; (10):36-9. PubMed ID: 3544240
    [No Abstract]   [Full Text] [Related]  

  • 30. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.
    Press MF; Gordon MA; Slamon DJ
    J Clin Oncol; 2012 Feb; 30(4):357-61. PubMed ID: 22203766
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
    Heidenreich A
    Urologe A; 1997 Nov; 36(6):568. PubMed ID: 9487597
    [No Abstract]   [Full Text] [Related]  

  • 32. Toremifene citrate (Fareston).
    Gerken P
    Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
    [No Abstract]   [Full Text] [Related]  

  • 33. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin.
    Okamoto T; Ogata J; Minami K
    Anesth Analg; 2003 Jul; 97(1):19-20, table of contents. PubMed ID: 12818936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of PET/CT for predicting of neoadjuvant chemotherapy response.
    Seemann MD
    Eur J Med Res; 2007 Feb; 12(2):90-1. PubMed ID: 17369123
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of the validity of a population pharmacokinetic model for epirubicin.
    Ralph LD; Sandstrom M; Twelves C; Dobbs NA; Thomson AH
    Br J Clin Pharmacol; 2006 Jul; 62(1):47-55. PubMed ID: 16842378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epirubicin-induced oxidative DNA damage and evidence for its repair in lymphocytes of cancer patients who are undergoing chemotherapy.
    Olinski R; Jaruga P; Foksinski M; Bialkowski K; Tujakowski J
    Mol Pharmacol; 1997 Nov; 52(5):882-5. PubMed ID: 9351979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer.
    Peláez I; Lacave AJ; Palacio I; Alvarez E; Cueva JF; Muñiz I; Arranz F; Fra J
    Eur J Cancer; 1996 May; 32A(5):899-900. PubMed ID: 9081375
    [No Abstract]   [Full Text] [Related]  

  • 39. Addition of histone deacetylase inhibitors in combination therapy.
    Carraway HE; Gore SD
    J Clin Oncol; 2007 May; 25(15):1955-6. PubMed ID: 17513801
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
    Czejka M; Bandak S; Simon D; Schüller J; Weiss C; Schernhammer E
    Z Naturforsch C J Biosci; 1995; 50(7-8):565-70. PubMed ID: 7546045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.